TMH/nf 01/23/06 4630-66461-04 476034 672

10/565717 1AP20 Regulation 23 Jan 2006

Express Mail No. EV668455236US Date of Deposit: January 23, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew et al.

Application No.

Filed: Herewith

Confirmation No.

For: NATURAL ASTAXANTHIN EXTRACT

REDUCES DNA OXIDATION

Examiner: Art Unit:

Attorney Reference No. 4630-66461-04

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450


<u>PURSUANT TO 37 C.F.R. § 1.97(b)(2)</u>

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to the deposit account referenced in the accompanying transmittal letter.

TMH/nf 01/23/06 4630-66461-04 476034 672



Express Mail No. EV668455236US Date of Deposit: January 23, 2006

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

B

Tanya M. Harding, Ph.D Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4630-66461-04
Application Number	801303111
Filing Date	
First Named Inventor	Chew
Art Unit	
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
	· · · · · · · · · · · · · · · · · · ·	FARE		

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee			
		WIPO	WO 96/13255 A (PCT/US95/14502)	05/09/1996	Board of Trustees of the University of Illinois			
		Japan	JP 02049091 A	02/19/1990	Suntory Ltd			
Examiner's Initials*	Cite No.	THE DIMENTS						
		CHEW et al., "A Comparison of the Anticancer Activities of Dietary β-Carotene, Canthaxanthin and Astaxanthin in Mice in Vivo," Anticancer Research, Vol. 19, No. 3A, May 1999 CRONIN, "The Potential of Astaxanthin: A New Multipurpose, High-Power Antioxidant,"						
		Alternative & Co	& Complementary Therapies, United States, Vol. 8, No. 1, February 2002					
					numan health and nutrition," ited Kingdom, Vol. 21, No. 5,			
		Physiological Ch	emistry and Physics and	l Medical NMR, Vol. 2				
		Journal of Clinic	al Biochemistry and Nu	trition, Vol. 16, No. 3, 1				
			"Effects of Astaxanthin VS, Vol. 44, No. 6, June		-Induced Inflammation in Vitro			
				s for the treatment of ag United Kingdom, Vol. 1	e-related macular degeneration," 0, No. 3, 2000			

EXAMINER DATE CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.